Abstract
Understanding the genomic impact of carcinogens is fundamental to cancer biology and prevention. However, recent coordinated efforts to detect such fingerprints have been largely unsuccessful, challenging the paradigm that carcinogens induce identifiable mutational signatures. Here we introduce a new method based on statistics from population genetics, signature variability analysis (SVA), that elucidates both the diversity of tumorcausing processes and the heterogeneity of population carcinogen exposure. When we use SVA to re-analyze four prominent studies commonly cited as evidence of nonmutagenic carcinogens, we find that tumors induced by environmental carcinogens do possess mutational signature patterns that distinguish them from spontaneous tumors, even if a specific mutational signature cannot be detected. We find that, across cancers, organs, and model organisms, carcinogen exposure generally increases both the diversity of mutational signatures within a tumor and the homogeneity of signature activity across subjects. Importantly, we show that this increase in signature diversity, far from being a background effect, is associated with the geographic incidence of cancer and can facilitate the acquisition of cancer driver mutations. Our results both encourage a re-examination of the genomic impact of numerous substances and introduce new tools for the analysis of the genomic effects of other substances, potentially influencing carcinogen classifications and cancer prevention policies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support was provided by a France-Stanford Center for Interdisciplinary Studies grant (NAR, NA, and MF), a US Department of Defense grant (RA210061 to MF and LFC), a French Agence Nationale de la Recherche grant (Tremplin program 2023 to LFC), a National Science Foundation Graduate Research Fellowship (MLM), the Anne T. and Robert M. Bass Stanford Graduate Fellowship (MLM), and a PhD fellowship from the French Ligue Nationale Contre le Cancer (LM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data. We used the SBS (96 types) and CN (48 types) COSMIC signatures called in 115 malignant pleural mesothelioma samples from the French MESOBANK (Supplementary Table from Mangiante et al. 2023) and corresponding signature definitions (COSMIC3.1, Table S35 from Mangiante et al. 2023). We used the 8 SBS COSMIC signatures and 3 de novo signatures from mice exposed to 20 different carcinogens (github repository https://github.com/team113sanger/mouse-mutatation-signatures containing the data and scripts from Riva et al 2020), focusing on the 58 lung and 112 liver tumors because they were the only ones including spontaneous tumors that serve as a control. We used the 14 SBS signatures from 232 LCINS, among which 213 have passive smoking information (personal communication with authors from Zhang et al. 2021} to obtain the source data for Figure 4 panel 6) and corresponding signature definitions (COSMIC v3, Table S7 from Zhang et al. 2021); note that in the original paper and thus here, samples where SBS4 was detected were removed from the analysis. We used the SBS signatures from n=88 lung adenocarcinoma in East Asians from the CHG cohort (Chen et al. 2020). We used the COSMIC SBS, DBS, and ID signatures from 552 ESCC samples from 8 countries (Table S15 from Moody et al. 2021) and the SBS, DBS, and ID signatures from 957 out of the 962 clear cell RCC samples from 11 countries (Table S6 from Senkin et al. biorxiv 2023; we excluded samples from Thailand because of their small sample size of n=5).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵4 email: alcalan{at}iarc.who.int
